AKT1 and colorectal carcinoma: The effect on the response to cetuximab in the setting of the three most common AKT1 activating mutations found in CRC patients (i.e., E17K, E49K, and L52R) was recently investigated by overexpressing them in a cetuximab-sensitive KRAS-wt CRC cell line.